Biotest

Companies Biotest

News Biotest

• Biotest AG: First time Revenue and EBIT contribution by Biotherapeutics Segment

  The Biotest Group has increased sales in the first half of 2011 in it's continuing operations (Plasma Proteins and Biotherapeutics) by 4,9 % to EUR 212,9 million compared to EUR 202.9 million in the previous year period. The increase was largely attributable to an upfront payment under a development more

• Merck Millipore Completed Acquisition of Microbiology Business of Biotest AG

  Merck Millipore announced that it has completed the acquisition of the microbiology business of Biotest AG, Dreieich, Germany. All relevant authorities approved the sale of Biotest´s woldwide Microbiological Monitoring business activities, which consist of the product portfolio of Hycon (hygiene mon more

• Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases

  Abbott and Biotest AG announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently in Phase II clinical trials for RA and psoriasis, with preclinical studies underway to study its potenti more

Publications Biotest

• Deal watch: Boosting TRegs to target autoimmune disease

  Deal watch: Boosting TRegs to target autoimmune disease Nature Reviews Drug Discovery 10, 566 (2011). doi:10.1038/nrd3517 Abbott Laboratories and Biotest Pharmaceuticals have entered into an agreement to co-develop BT-061, a humanized CD4-specific monoclonal antibody that is c more

• Effect of organic and inorganic toxic compounds on luminescence of luminous fungi

  The possibility of the development of the solid phase bioluminescent biotest using aerial mycelium of luminous fungi was investigated. Effect of organic and inorganic toxic compounds (TC) at concentrations from 10−6 to 1 mg/ml on luminescence of aerial mycelia of four species of luminous fungi—Armil more

• Anti‐EBNA‐1 IgG is not a reliable marker of multiple sclerosis clinical disease activity

  Background:  Sero‐epidemiological studies have demonstrated the association between multiple sclerosis (MS) and prior Epstein–Barr virus (EBV) infection. It has been hypothesized that intermittent peripheral EBV reactivation may drive continuing central inflammation. Recent investigation has shown more

Websites Biotest